Pharmaceutical intermediates
Nintedanib Esylate Intermediates
5 pharmaceutical intermediates for Nintedanib Esylate. Indication: Systemic sclerosis-related interstitial lung disease; Idiopathic pulmonary fibrosis; Non-small cell lung cancer.
About Nintedanib Esylate
- Originator
- Boehringer Ingelheim
- Indication
- Systemic sclerosis-related interstitial lung disease; Idiopathic pulmonary fibrosis; Non-small cell lung cancer
- Approved Date
- 10/15/2014
- DS/DP
- 10/01/2025
Available intermediates
5 intermediates currently listed for Nintedanib Esylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide | 2653-16-9 | / | / |
| Trimethyl orthobenzoate | 707-07-3 | / | / |
| N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin -1-yl)acetamide | 262368-30-9 | / | / |
| Methyl 2-oxoindole-6-carboxylate | 14192-26-8 | / | / |
| (3E)-2,3-Dihydro-3-(methoxyphenylmethylene) -2-oxo-1H-indole-6- carboxylic acid methyl ester | 1168150-46-6 | / | / |
Building toward Nintedanib Esylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →